Developer docs
API playgroundTry for free, no card

Search company profiles

Recce Pharmaceuticals

Full company profile

uuid0005rv9

Namestring
Recce Pharmaceuticals
Legal namestring
Recce Pharmaceuticals Ltd
Websiteurl
recce.com.au
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Recce Pharmaceuticals Ltd (ASX: RCE) is an Australian clinical-stage biopharmaceutical company founded in 2008 and headquartered in Sydney. It is developing RECCE® 327 Topical Gel, a synthetic polymer-based broad-spectrum anti-infective designed to treat diabetic foot infections (DFI). The product is administered as a topical gel and is positioned against a therapeutic area with limited effective options, particularly for moderate infections and infected ulcers below the knee.

The company's underlying technology is a proprietary polymer-antibiotic platform anchored by a single lead asset, RECCE® 327. Following HREC approval in 2026, the asset advanced into pivotal Phase 3 registrational trials. Recce is running two parallel registrational Phase 3 studies — one in Australia and one in Indonesia — with full enrollment targeted by the end of 2027. The Phase 3 protocol was expanded from mild-only infections to include moderate infections, increasing the addressable patient population to approximately 80% of DFI presentations. The company is pursuing multi-jurisdiction registration across Australia, the United States, MENA, and ASEAN.

Recce Pharmaceuticals is pre-revenue and currently generates no product sales. Its business model is to develop and ultimately commercialize RECCE® 327 Topical Gel through traditional pharmaceutical distribution channels — hospital pharmacies, specialty pharmacies, and healthcare provider networks — supported by a field sales organization targeting hospital systems, wound care clinics, and diabetic foot treatment specialists post-approval. Until then, the company is funded primarily through periodic equity raises (with disclosed tranches of roughly AUD 20.0M in 2020, AUD 8.0M in 2023, AUD 2.0M in 2024 including U.S. Department of Defense support, and AUD 3.1M in 2025) and is led by CEO James Graham, CSO/Executive Director Michele Dilizia, and VP Translational Sciences Philip Sutton.

Short descriptiontext

Recce Pharmaceuticals is an Australian clinical-stage biopharmaceutical company (ASX: RCE) developing RECCE® 327 Topical Gel, a synthetic polymer antibiotic for diabetic foot infections, currently advancing through parallel registrational Phase 3 trials in Australia and Indonesia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
synthetic polymer antibiotics, anti-infective pharmaceuticals, topical antibiotic gel, diabetic foot infections, broad-spectrum antibiotics
Industry1 code
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Anti-infective pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1RECCE® 327 Topical Gel commercialization
TypeOne Time License
Description

Recce Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel anti-infective drugs. Revenue will be generated through the sale of approved pharmaceutical products, specifically RECCE® 327 Topical Gel upon regulatory approval and commercialization across targeted markets including Australia, United States, MENA, and ASEAN regions.

finance.yahoo.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RECCE® 327
Description

RECCE® 327 Topical Gel - Company's lead anti-infective drug candidate for diabetic foot infections

finance.yahoo.com
Core offering1 text field

Recce Pharmaceuticals develops RECCE® 327 Topical Gel, a novel synthetic polymer-based broad-spectrum anti-infective drug candidate formulated for the topical treatment of diabetic foot infections (DFI). The product is currently in two parallel registrational Phase 3 clinical trials in Australia and Indonesia, with an expanded protocol covering mild to moderate infections and infected ulcers below the knee, addressing approximately 80% of DFI presentations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Recce Pharmaceuticals is a clinical-stage biopharmaceutical company developing RECCE® 327 Topical Gel, a novel anti-infective drug candidate for diabetic foot infections. The company is currently conducting two parallel registrational Phase 3 clinical trials in Australia and Indonesia, targeting global registration across Australia, the United States, MENA, and ASEAN markets. The product is a single topical gel formulation.

Product and service1 record
1RECCE® 327 Topical Gel
CategoryAnti-infective pharmaceuticals
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PolyPid is a clinical-stage biopharmaceutical company developing polymer-based drug delivery and anti-infective therapeutics; highly comparable on technology platform (polymer-based anti-infective) and clinical-stage structure targeting surgical-site and similar infection indications.

TypeDirect peer
Description

Spero Therapeutics is a clinical-stage antibiotics developer focused on novel mechanisms to address resistant bacterial infections, including topical anti-infective candidates; directly comparable as a small-cap anti-infective specialist pursuing regulatory approval in similar indications.

TypeBroad incumbent
Description

Smith & Nephew is a large diversified medical device company with a major advanced wound care franchise serving diabetic foot ulcer and wound infection markets; comparable as a competing commercial player in the same DFI/wound care category.

TypeDirect peer
Description

ContraFect is a clinical-stage biotech developing direct lytic and other novel anti-infective agents targeting serious bacterial infections; comparable on business model (clinical-stage anti-infectives) and category (novel-mechanism antibiotics).

TypeDirect peer
Description

Organogenesis is a wound care and regenerative medicine company marketing advanced wound care products for chronic wounds including diabetic foot ulcers; comparable on target indication (DFU/DFI) and topical/wound care commercial model.

TypeBroad incumbent
Description

Integra LifeSciences has a dedicated wound care portfolio including regenerative skin substitutes and topical solutions for diabetic foot ulcers and complex wounds; comparable as a wound care incumbent and potential M&A consolidator of DFI therapies.

TypeBroad incumbent
Description

Coloplast operates a global wound and skin care business including wound dressings and products for diabetic foot ulcers; comparable as an established wound care incumbent addressing the same patient population.

TypeDirect peer
Description

MiMedx develops and commercializes regenerative wound care and surgical products for chronic wounds including diabetic foot ulcers; comparable on target indication and wound care specialty pharmacy/channel strategy.

TypeBroad incumbent
Description

Convatec is a global wound care, ostomy, and continence company with established products for diabetic foot ulcers and wound infections; comparable as an established wound care incumbent in the same target indication.

TypeDirect peer
Description

Destiny Pharma developed XF-73, a topical antimicrobial gel targeting infection-related indications including surgical site infections; closely comparable as a small-cap clinical-stage anti-infective developer with a topical gel asset.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Recce Pharmaceuticals

Anti-infective pharmaceuticalsrecce.com.au

Recce Pharmaceuticals is an Australian clinical-stage biopharmaceutical company (ASX: RCE) developing RECCE® 327 Topical Gel, a synthetic polymer antibiotic for diabetic foot infections, currently advancing through parallel registrational Phase 3 trials in Australia and Indonesia.

What Recce Pharmaceuticals does

Recce Pharmaceuticals Ltd (ASX: RCE) is an Australian clinical-stage biopharmaceutical company founded in 2008 and headquartered in Sydney. It is developing RECCE® 327 Topical Gel, a synthetic polymer-based broad-spectrum anti-infective designed to treat diabetic foot infections (DFI). The product is administered as a topical gel and is positioned against a therapeutic area with limited effective options, particularly for moderate infections and infected ulcers below the knee.

The company's underlying technology is a proprietary polymer-antibiotic platform anchored by a single lead asset, RECCE® 327. Following HREC approval in 2026, the asset advanced into pivotal Phase 3 registrational trials. Recce is running two parallel registrational Phase 3 studies — one in Australia and one in Indonesia — with full enrollment targeted by the end of 2027. The Phase 3 protocol was expanded from mild-only infections to include moderate infections, increasing the addressable patient population to approximately 80% of DFI presentations. The company is pursuing multi-jurisdiction registration across Australia, the United States, MENA, and ASEAN.

Recce Pharmaceuticals is pre-revenue and currently generates no product sales. Its business model is to develop and ultimately commercialize RECCE® 327 Topical Gel through traditional pharmaceutical distribution channels — hospital pharmacies, specialty pharmacies, and healthcare provider networks — supported by a field sales organization targeting hospital systems, wound care clinics, and diabetic foot treatment specialists post-approval. Until then, the company is funded primarily through periodic equity raises (with disclosed tranches of roughly AUD 20.0M in 2020, AUD 8.0M in 2023, AUD 2.0M in 2024 including U.S. Department of Defense support, and AUD 3.1M in 2025) and is led by CEO James Graham, CSO/Executive Director Michele Dilizia, and VP Translational Sciences Philip Sutton.

Recce Pharmaceuticals firmographics

Firmographics
Name
Recce Pharmaceuticals
Legal name
Recce Pharmaceuticals Ltd
Website
https://recce.com.au
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Recce Pharmaceuticals is an Australian clinical-stage biopharmaceutical company (ASX: RCE) developing RECCE® 327 Topical Gel, a synthetic polymer antibiotic for diabetic foot infections, currently advancing through parallel registrational Phase 3 trials in Australia and Indonesia.
Ownership category
akta.pro rank

Recce Pharmaceuticals industry classification

Industry
Product category
Anti-infective pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Synthetic polymer antibiotics
  • Anti-infective pharmaceuticals
  • Topical antibiotic gel
  • Diabetic foot infections
  • Broad-spectrum antibiotics

Where Recce Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Markets served

Recce Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. RECCE® 327 Topical Gel commercialization: Recce Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel anti-infective drugs. Revenue will be generated through the sale of approved pharmaceutical products, specifically RECCE® 327 Topical Gel upon regulatory approval and commercialization across targeted markets including Australia, United States, MENA, and ASEAN regions.

Go-to-market motion1 record

Recce Pharmaceuticals product offering

Product offering

Core offering

Recce Pharmaceuticals develops RECCE® 327 Topical Gel, a novel synthetic polymer-based broad-spectrum anti-infective drug candidate formulated for the topical treatment of diabetic foot infections (DFI). The product is currently in two parallel registrational Phase 3 clinical trials in Australia and Indonesia, with an expanded protocol covering mild to moderate infections and infected ulcers below the knee, addressing approximately 80% of DFI presentations.

Product overview

Recce Pharmaceuticals is a clinical-stage biopharmaceutical company developing RECCE® 327 Topical Gel, a novel anti-infective drug candidate for diabetic foot infections. The company is currently conducting two parallel registrational Phase 3 clinical trials in Australia and Indonesia, targeting global registration across Australia, the United States, MENA, and ASEAN markets. The product is a single topical gel formulation.

Differentiator

Problem solved

Functional benefit

Brands

  • RECCE® 327: RECCE® 327 Topical Gel - Company's lead anti-infective drug candidate for diabetic foot infections

Products and services

  • RECCE® 327 Topical Gel

Companies that use Recce Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Recce Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Recce Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Recce Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • PolyPid: PolyPid is a clinical-stage biopharmaceutical company developing polymer-based drug delivery and anti-infective therapeutics; highly comparable on technology platform (polymer-based anti-infective) and clinical-stage structure targeting surgical-site and similar infection indications.
  • Spero Therapeutics: Spero Therapeutics is a clinical-stage antibiotics developer focused on novel mechanisms to address resistant bacterial infections, including topical anti-infective candidates; directly comparable as a small-cap anti-infective specialist pursuing regulatory approval in similar indications.
  • ContraFect Corporation: ContraFect is a clinical-stage biotech developing direct lytic and other novel anti-infective agents targeting serious bacterial infections; comparable on business model (clinical-stage anti-infectives) and category (novel-mechanism antibiotics).
  • Organogenesis Holdings: Organogenesis is a wound care and regenerative medicine company marketing advanced wound care products for chronic wounds including diabetic foot ulcers; comparable on target indication (DFU/DFI) and topical/wound care commercial model.
  • MiMedx Group: MiMedx develops and commercializes regenerative wound care and surgical products for chronic wounds including diabetic foot ulcers; comparable on target indication and wound care specialty pharmacy/channel strategy.
  • Destiny Pharma: Destiny Pharma developed XF-73, a topical antimicrobial gel targeting infection-related indications including surgical site infections; closely comparable as a small-cap clinical-stage anti-infective developer with a topical gel asset.

Broad incumbents

  • Smith & Nephew: Smith & Nephew is a large diversified medical device company with a major advanced wound care franchise serving diabetic foot ulcer and wound infection markets; comparable as a competing commercial player in the same DFI/wound care category.
  • Integra LifeSciences: Integra LifeSciences has a dedicated wound care portfolio including regenerative skin substitutes and topical solutions for diabetic foot ulcers and complex wounds; comparable as a wound care incumbent and potential M&A consolidator of DFI therapies.
  • Coloplast: Coloplast operates a global wound and skin care business including wound dressings and products for diabetic foot ulcers; comparable as an established wound care incumbent addressing the same patient population.
  • Convatec Group: Convatec is a global wound care, ostomy, and continence company with established products for diabetic foot ulcers and wound infections; comparable as an established wound care incumbent in the same target indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Recce Pharmaceuticals social profiles

Digital presence

Recce Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Recce Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Recce Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Recce Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Recce Pharmaceuticals

What does Recce Pharmaceuticals do?

Recce Pharmaceuticals develops RECCE® 327 Topical Gel, a novel synthetic polymer-based broad-spectrum anti-infective drug candidate formulated for the topical treatment of diabetic foot infections (DFI). The product is currently in two parallel registrational Phase 3 clinical trials in Australia and Indonesia, with an expanded protocol covering mild to moderate infections and infected ulcers below the knee, addressing approximately 80% of DFI presentations.

Is Recce Pharmaceuticals a public or private company?

Recce Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Recce Pharmaceuticals founded?

Recce Pharmaceuticals was founded in 2007. It employs 11 to 50 people.

Where is Recce Pharmaceuticals based?

Recce Pharmaceuticals is headquartered in Sydney, Australia, in the Oceania region.

How does Recce Pharmaceuticals make money?

One revenue line is on record: RECCE® 327 Topical Gel commercialization.

Who are Recce Pharmaceuticals's main competitors?

Direct peers on record are PolyPid, Spero Therapeutics, ContraFect Corporation, Organogenesis Holdings, MiMedx Group and Destiny Pharma. Broad incumbents are Smith & Nephew, Integra LifeSciences, Coloplast and Convatec Group.

Does Recce Pharmaceuticals have an API?

No public API is recorded for Recce Pharmaceuticals.

What industry is Recce Pharmaceuticals in?

Recce Pharmaceuticals's product category is Anti-infective pharmaceuticals. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ProactiveinvestorsRecce’s R327G gains commercial pathway with Arrotex - ICYMIRecce Pharmaceuticals signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for R327G topical gel in Australia and New Zealand. The deal lets Recce retain manufacturing and IP while Arrotex handles sales and distribution. Recce expects Phase 3 data later next year, with potential regulatory submissions and further licensing as catalysts.EIN PresswireRecce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data reviewRecce Pharmaceuticals' Phase 3 diabetic foot infection trial will have an independent Data Monitoring Committee review unblinded efficacy and safety data after a blinded review showed encouraging outcomes. The committee will assess 75 patients from the 90 enrolled, with a meeting expected by mid-November 2026. Recommendations could include progressing to regulatory submission or pausing the trial.ProactiveinvestorsRecce Pharmaceuticals advances R327 as diabetes and antibiotic resistance burdens convergeRecce Pharmaceuticals is advancing R327, a topical anti-infective for diabetic foot infections, through two Phase 3 trials in Indonesia and Australia. The Indonesian trial's interim analysis is planned for September 2026, with commercialisation targeted for 2027. The company also has a non-binding term sheet for a Middle Eastern licensing deal.ProactiveinvestorsRecce Pharmaceuticals secures HREC approval for expanded Phase 3 diabetic foot infection trialRecce Pharmaceuticals has received Australian Human Research Ethics Committee (HREC) approval to expand its Phase 3 trial for RECCE® 327 Topical Gel by adding a 208-patient active-controlled study arm. This amendment introduces a non-inferiority comparison against physician-selected antibiotics, with patient dosing and recruitment already underway under the existing protocol. The expanded trial aims to generate comparative clinical data to support regulatory submissions in Australia, the US, and other international markets.Kalkine MediaWhich ASX Healthcare Stocks Advanced Through Clinical and Regulatory Milestones?Singular Health, Imagion Biosystems, Recce Pharmaceuticals, and Alterity Therapeutics reported meaningful operational and development milestones in the healthcare sector during the quarter. Their activities include advancements in digital medical imaging, cancer diagnostics, anti-infective therapies, and treatments for neurological diseases. Progress in regulatory matters is crucial for these companies to advance clinical development and support future commercialization efforts.MarketScreenerRecce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures StrategyRecce Pharmaceuticals is positioned to benefit from the US ASPR Medical Countermeasures Strategy due to its development of synthetic anti-infectives targeting antibiotic-resistant superbugs and viral pathogens. The company's pipeline includes RECCE 327, RECCE 435, and RECCE 529, which are designed to overcome bacterial and viral resistance mechanisms. This alignment suggests potential strategic advantages for Recce in addressing global health challenges through its specialized therapeutic offerings.AInvestRecce Pharmaceuticals Ltd-Vietnamese patent granted for Recce anti-infectivesRecce Pharmaceuticals Ltd has secured a patent in Vietnam for its anti-infective compounds, including RECCE 327 and RECCE 529, valid until 2033. The patent is part of the company's broader global intellectual property expansion, following recent approvals in Australia, China, and Hong Kong. The company now holds four wholly owned patent families encompassing over 40 patents and applications worldwide, including protections in the United States, Europe, Japan, and other key markets.AInvestWhy Recce Pharmaceuticals Keeps Filing Cleansing NoticesRecce Pharmaceuticals filed a cleansing notice with the Australian Securities Exchange on July 1, 2026, following completion of a share placement raising approximately A$4 million at A$0.40 per share, involving 10 million new shares sold to professional investors. The company also opened a share purchase plan for eligible shareholders starting July 6 at the same price, and received a A$3.67 million income tax refund from the Australian Taxation Office, primarily from overseas R&D tax incentives. The article frames this as part of a recurring pattern in small-cap biotech financing where the company funds itself through equity issuance, noting retail investors hold roughly 55% ownership while insiders hold about 25%, with institutional holders shifting as the share count expands.YahooRecce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestonesRecce Pharmaceuticals Ltd received a A$3.67 million income tax refund from the Australian Taxation Office, comprising A$3.57 million in overseas R&D expenditure plus A$95,826 in interest, lifting the company's pro-forma cash position to approximately A$33.1 million. The biotech company recently completed a A$4 million placement to institutional investors and is preparing a share purchase plan targeting up to another A$4 million. The funding will support Phase 3 clinical trials for diabetic foot infections in Australia and Indonesia, commercial licensing discussions with a Middle Eastern pharmaceutical partner, and regulatory filings with the FDA and BPOM.